{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:58:22Z","timestamp":1787990302920,"version":"build-2784847793"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aims of this clinical review are to: (i) highlight the importance of elevated baseline triglycerides (TG) in the setting of well-controlled low-density lipoprotein cholesterol (LDL-C) on statins as a major contributor to residual atherosclerotic cardiovascular disease (ASCVD) risk, particularly among patients with type 2 diabetes mellitus, metabolic syndrome, and obesity whose distinctive lipid phenotype cannot be optimally treated with LDL-C reduction therapy alone; (ii) describe the findings and clinical implications of the landmark REDUCE-IT trial in which ethyl eicosapentaenoic acid significantly improved ASCVD outcomes. While many genetic studies have shown that elevated TG are an independent causal factor for ASCVD, prior placebo-controlled trials using niacin, fibrates, omega-3 fatty acids, and dietary supplement fish oil preparations have failed to demonstrate significant CV event reduction when added to statin therapy. In contrast, the REDUCE-IT trial in 8179 participants showed convincingly that the administration of 4 g daily of icosapent ethyl (an ethyl ester of eicosapentaenoic acid) in patients at high risk for ASCVD with increased levels of baseline TG [median value, 2.44\u2009mmol\/L (216.0\u2009mg\/dL)] but well-controlled LDL-C [median value, 1.94\u2009mmol\/L (75.0\u2009mg\/dL)] reduced significantly incident events across both the trial primary endpoint and multiple prespecified secondary endpoints, including cardiovascular death, as well as both subsequent and total primary endpoint and key secondary endpoint events. Icosapent ethyl unequivocally contributed to ASCVD event reduction over and above statin therapy. The REDUCE-IT trial results should alter our approach to managing a growing population of hypertriglyceridaemic patients whose lipid phenotype requires more intensive treatment beyond LDL-C lowering alone.<\/jats:p>\n               <jats:p\/>","DOI":"10.1093\/eurheartj\/ehz778","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T19:20:38Z","timestamp":1571685638000},"page":"2304-2312","source":"Crossref","is-referenced-by-count":72,"title":["Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7145-8084","authenticated-orcid":false,"given":"William E","family":"Boden","sequence":"first","affiliation":[{"name":"VA New England Healthcare System, Boston University School of Medicine , 150 S. Huntington Avenue, Boston, MA 02130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital Heart & Vascular Center , Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P","family":"Toth","sequence":"additional","affiliation":[{"name":"CGH Medical Center , Sterling, IL, USA"},{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention, School of Public Health , Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M John","family":"Chapman","sequence":"additional","affiliation":[{"name":"Sorbonne University, Pitie-Salpetriere University Hospital , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F","family":"L\u00fcscher","sequence":"additional","affiliation":[{"name":"University Heart Center, University Hospital , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"2022102617030269700_ehz778-B1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B2","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.jacc.2017.09.001","article-title":"How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD","volume":"70","author":"Hong","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102617030269700_ehz778-B3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102617030269700_ehz778-B4","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"2022102617030269700_ehz778-B5","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2337\/db16-0046","article-title":"Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol","volume":"65","author":"Xiao","year":"2016","journal-title":"Diabetes"},{"key":"2022102617030269700_ehz778-B7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","article-title":"Unmet need for adjunctive dyslipidemia therapy in hypertriglyderidemia management","volume":"72","author":"Ganda","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102617030269700_ehz778-B8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/jamacardio.2016.4396","article-title":"Trends in total cholesterol, triglycerides, and low-density lipoprotein in US adults, 1999-2014","volume":"2","author":"Rosinger","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2022102617030269700_ehz778-B9","first-page":"S9","article-title":"Dyslipidaemia and atherosclerotic vascular disease: DYSIS results in the UK","volume":"20","author":"Amber","year":"2013","journal-title":"Br J Cardiol"},{"key":"2022102617030269700_ehz778-B10","doi-asserted-by":"crossref","first-page":"160.","DOI":"10.1186\/s12872-017-0591-5","article-title":"Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study","volume":"17","author":"Halcox","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2022102617030269700_ehz778-B11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jacl.2018.11.008","article-title":"Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey","volume":"13","author":"Fan","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2022102617030269700_ehz778-B12","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","article-title":"Triglycerides on the rise: should we swap seats on the seesaw?","volume":"36","author":"Libby","year":"2015","journal-title":"Eur Heart J"},{"key":"2022102617030269700_ehz778-B13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCRESAHA.115.306398","article-title":"Surprises from genetic analyses of lipid risk factors for atherosclerosis","volume":"118","author":"Musunuru","year":"2016","journal-title":"Circ Res"},{"key":"2022102617030269700_ehz778-B14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102617030269700_ehz778-B15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"2022102617030269700_ehz778-B18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrg.2016.160","article-title":"Genetics of coronary artery disease: discovery, biology and clinical translation","volume":"18","author":"Khera","year":"2017","journal-title":"Nat Rev Genet"},{"key":"2022102617030269700_ehz778-B19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2022102617030269700_ehz778-B20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002765","article-title":"Remnant lipoprotein cholesterol and incident coronary heart disease: the Jackson Heart and Framingham Offspring Cohort Studies","volume":"5","author":"Joshi","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2022102617030269700_ehz778-B21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.pharmthera.2013.11.008","article-title":"Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment","volume":"141","author":"Varbo","year":"2014","journal-title":"Pharmacol Ther"},{"key":"2022102617030269700_ehz778-B22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022102617030269700_ehz778-B23","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"2022102617030269700_ehz778-B24","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B25","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.amjcard.2012.07.007","article-title":"Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials","volume":"110","author":"Robinson","year":"2012","journal-title":"Am J Cardiol"},{"key":"2022102617030269700_ehz778-B26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B27","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides and Impact on Global Health Outcomes)","volume":"62","author":"Guyton","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022102617030269700_ehz778-B28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbalip.2011.10.011","article-title":"Fish oil\u2014how does it reduce plasma triglycerides?","volume":"1821","author":"Shearer","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2022102617030269700_ehz778-B29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jacl.2011.10.018","article-title":"Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review","volume":"6","author":"Jacobson","year":"2012","journal-title":"J Clin Lipidol"},{"key":"2022102617030269700_ehz778-B30","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1476-5381.2009.00290.x","article-title":"Resolvins and protectins: mediating solutions to inflammation","volume":"158","author":"Kohli","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2022102617030269700_ehz778-B31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"2022102617030269700_ehz778-B32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mayocp.2016.10.018","article-title":"A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk","volume":"92","author":"Alexander","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2022102617030269700_ehz778-B33","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1161\/CIR.0000000000000482","article-title":"Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association","volume":"135","author":"Siscovick","year":"2017","journal-title":"Circulation"},{"key":"2022102617030269700_ehz778-B34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/2012.jama.11374","article-title":"Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis","volume":"308","author":"Rizos","year":"2012","journal-title":"JAMA"},{"key":"2022102617030269700_ehz778-B35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(01)01114-7","article-title":"N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials","volume":"112","author":"Bucher","year":"2002","journal-title":"Am J Med"},{"key":"2022102617030269700_ehz778-B36","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/archinternmed.2012.262","article-title":"Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"172","author":"Kwak","year":"2012","journal-title":"Arch Intern Med"},{"key":"2022102617030269700_ehz778-B37","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"2022102617030269700_ehz778-B38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"key":"2022102617030269700_ehz778-B39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijcard.2016.11.105","article-title":"Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study","volume":"228","author":"Nosaka","year":"2017","journal-title":"Int J Cardiol"},{"key":"2022102617030269700_ehz778-B40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B41","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/eurheartj\/ehz179","article-title":"REDUCE-IT: Residual Cardiovascular Risk in Statin-Treated Patients with Elevated Triglycerides: Now We Can REDUCE-IT!","volume":"40","author":"Bhatt","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102617030269700_ehz778-B42","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102617030269700_ehz778-B43","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102617030269700_ehz778-B44","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B45","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B46","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2019.01.016","article-title":"Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease","volume":"73","author":"Picard","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102617030269700_ehz778-B47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMe1814004","article-title":"FISHing for the miracle of eicosapentaenoic acid","volume":"380","author":"Kastelein","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B48","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clin Cardiol"},{"key":"2022102617030269700_ehz778-B49","doi-asserted-by":"crossref","first-page":"2.","DOI":"10.1007\/s11883-019-0762-1","article-title":"New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease","volume":"21","author":"Preston Mason","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"2022102617030269700_ehz778-B50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2022102617030269700_ehz778-B51","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Collaborative Group","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102617030269700_ehz778-B53","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102617030269700_ehz778-B54","article-title":"National Lipid Association position on the use of icosapent ethyl in high and very high risk patients","volume":"2019","author":"Orringer","year":"2019","journal-title":"Clin Lipid Update"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/24\/2304\/46647119\/ehz778.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/24\/2304\/46647119\/ehz778.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T17:04:17Z","timestamp":1666803857000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/24\/2304\/5686013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":54,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2019,12,23]]},"published-print":{"date-parts":[[2020,6,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz778","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6,21]]},"published":{"date-parts":[[2019,12,23]]}}}